FDA approves donor lung preservation device that may result in more lung transplants

Today, the U.S. Food and Drug Administration approved the XVIVO Perfusion System (XPS) with STEEN Solution, a device for preserving donated lungs that do not initially meet the standard criteria for lung transplantation but may be transplantable if there is more time to observe and evaluate the organ’s function to determine whether the lung is viable for transplantation.
Source: Food and Drug Administration - Category: American Health Source Type: news

Related Links:

Human body is intertwined collection of lives of Individual organs.We believe death occurs when brain dies , respiration stops and circulation ceases . Curiously ,when life ends , these organs  don’t die as a single unit . These three events can happen in any of the six possible permutations.Each organ takes different times to die after loss of life.It is like a crashed computer , where the mother board /RAM memory may be transferred to another and be functional . Out of these three , heart function appears to be supreme as it can function without the need of brain (Science of brain-death) and keep the body...
Source: Dr.S.Venkatesan MD - Category: Cardiology Authors: Tags: Heart transplantation donor heart transport transmedics Source Type: blogs
Abstract A 44-year-old male with ongoing chest pain and left ventricular ejection fraction 400 s: multiple argatroban bolus doses were required, along with accelerated up-titration of infusion dosing. Despite maintaining an ACT>484 s, clot formation was observed in the cardiotomy reservoir prior to separation. Subsequently, the patient developed severe disseminated intravascular coagulopathy, with both intra-cardiac and intravascular thrombi, requiring massive transfusion and continuous cell saving due to severe hemorrhage post cardiopulmonary bypass (CPB). The patient received a total of 105 units of plasma, 7...
Source: Perfusion - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Perfusion Source Type: research
Lung transplantation is a lifesaving therapy for patients with end-stage lung disease, but donor shortage still represents a significant problem in the clinical practice. With the use of normothermic ex vivo lung perfusion (EVLP), the retrieved donor lungs are ventilated and perfused in an ex vivo circuit, allowing repair and extended assessment of marginal donor lungs before transplantation.1 Actual criteria used to evaluate lung suitability for transplantation during EVLP are lung function tests, radiographic and bronchoscopic findings and macroscopic assessment.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
We report the case of a 51-year-old patient who underwent bilateral lung transplantation and presented with an unstable condition and sepsis 6 days after transplantation. The performed contrast enhanced spectral detector computed tomography (CT) using a dual-layer detector showed absence of perfusion in the left lung on iodine maps, although branches of the pulmonary artery were patent. This prompted retrospective evaluation of CT images and total venous occlusion of the left pulmonary veins was found. Here, iodine maps helped in raising conspicuity of loss of lung perfusion.
Source: Indian Journal of Radiology and Imaging - Category: Radiology Authors: Source Type: research
Heart transplantation is the definitive treatment for end-stage heart failure. A shortage of donor hearts forced transplant programs to accept older donors and longer ischemic times. Previous studies have suggested that the administration of mesenchymal stem cells (MSCs) or their conditioned medium (CM) protects the heart against ischemia/reperfusion injury (IRI). We hypothesized that the preservation of donor hearts with a CM would protect the graft from IRI after prolonged storage in 15-month-old rats and investigated mRNA-changes attributable to CM.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Pre-Clinical Science Source Type: research
Ex vivo lung perfusion (EVLP) is used by an increasing number of transplant centres. It is still controversial whether an acellular or cellular (erythrocyte enriched) perfusate is preferable. The aim of this p...
Source: Respiratory Research - Category: Respiratory Medicine Authors: Tags: Research Source Type: research
Abstract Donors after brain death (DBD) have been the major source of organ donation due to good perfusion of the organs. However, owing to the mismatch in demand and supply of the organ donors and recipients, donors after circulatory death (DCDDs) has increased recently all over the world. Kidneys, liver, and lungs are being used for transplantation from DCDDs. Recently, heart transplantation from DCDDs has been started, which is under the firestorm of scrutiny by the ethicists. The ethical dilemma revolves around the question whether the donors are actually dead when they are declared dead by cardiocirculatory d...
Source: Indian Heart J - Category: Cardiology Authors: Tags: Indian Heart J Source Type: research
uri Francesco Blasi Ex vivo lung perfusion (EVLP) is an emerging procedure that allows organ preservation, assessment and reconditioning, increasing the number of marginal donor lungs for transplantation. However, physiological and airflow measurements are unable to unveil the molecular mechanisms responsible of EVLP beneficial effects on lung graft and monitor the proper course of the treatment. Thus, it is urgent to find specific biomarkers that possess these requirements but also accurate and reliable techniques that identify them. The purpose of this study is to give an overview on the potentiality of shotgun pro...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Purpose of review Recent progress in genetic engineering has facilitated development of transgenic donor animals designed to overcome the known barriers to discordant xenotransplantation, and greatly accelerated progress in the field of xenotransplantation. Here we review and summarize recent progress in lung xenotransplantation, and discuss possible additional genetic modifications and other interventions that may further advance the use of pulmonary xenografts towards clinical applications based on known mechanisms of xeno lung injury. Recent findings Ex-vivo lung perfusion experiments have shown that the addition o...
Source: Current Opinion in Organ Transplantation - Category: Surgery Tags: XENOTRANSPLANTATION: Edited by Andrew Adams Source Type: research
Ventricular assist devices (VADs) are currently standard therapy for patients with advanced heart failure that is refractory to medical therapy.1 VADs can be categorized as pulsatile flow VADs (PF-VADs) and continuous flow VADs (CF-VADs). Both PF-VADs and CF-VADs are similarly effective in providing hemodynamic benefit (augmenting cardiac output and end-organ perfusion, and reducing ventricular work), and improving the quality of life and functional capacity of patients.2,3 CF-VADs are preferred over the PF-VADs due to advantages including compact size, reliability, energy efficiency, ease of implantation, and operation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Pre-Clinical Science Source Type: research
More News: American Health | Food and Drug Administration (FDA) | Lung Transplant | Perfusion | Transplants